Cell & Gene Therapy
Tricida Pharma's revolutionary gene therapy platforms are showing unprecedented efficacy in treating rare genetic disorders. We are rewriting the future of curative medicine.
The Future of Medicine
Our cell and gene therapy programs represent the cutting edge of modern medicine, offering hope for patients with previously untreatable genetic disorders. Using advanced viral vectors and CRISPR technology, we're rewriting the genetic code to cure disease at its source.
With breakthrough therapies in clinical development and multiple FDA Fast Track designations, we're pioneering the next generation of curative treatments.
Learn MoreOur Technologies
Advanced platforms for next-generation therapeutics
AAV Gene Therapy
Adeno-associated viral vectors delivering therapeutic genes with high efficiency and safety profiles.
CRISPR Gene Editing
Precise genome editing technology for permanent correction of genetic mutations at the DNA level.
CAR-T Cell Therapy
Engineered immune cells programmed to target and destroy cancer cells with unprecedented specificity.
mRNA Therapeutics
Messenger RNA technology enabling rapid development of vaccines and protein replacement therapies.
Stem Cell Therapy
Pluripotent and adult stem cells for tissue regeneration and treatment of degenerative diseases.
Gene Silencing
RNAi and antisense oligonucleotides for targeted suppression of disease-causing genes.
Target Disease Areas
Developing curative therapies for the most challenging diseases
Rare Genetic Disorders
Targeting rare monogenic diseases including hemophilia, muscular dystrophy, and inherited metabolic disorders with curative gene therapies.
Oncology
CAR-T and other cell therapies for hematologic malignancies and solid tumors, offering new hope for patients with treatment-resistant cancers.
Neurological Disorders
Gene therapies crossing the blood-brain barrier to treat neurodegenerative diseases including Parkinson's, Alzheimer's, and ALS.
Cardiovascular Disease
Novel gene and cell therapies for heart failure, inherited cardiomyopathies, and vascular diseases.
Clinical Pipeline
Leading programs advancing through clinical development
Single-dose AAV gene therapy demonstrating sustained factor IX expression and elimination of bleeding events in 90% of patients.
Next-generation CAR-T cell therapy with improved persistence and reduced toxicity profile showing 85% complete response rate.
Micro-dystrophin gene therapy restoring muscle function in pediatric patients with promising safety and efficacy data.
Transform Lives with Gene Therapy
Partner with us to develop the next generation of curative therapies